Plasma Tau and MRI Mismatch Identifies Rapid Alzheimer's Decline

The clinical management of Alzheimer's disease is shifting with the approval of amyloid-targeting monoclonal antibodies, yet the biological drivers of cognitive decline remain remarkably heterogeneous [1, 2]. While the traditional research framework defines the disease through the presence of amyloid, tau, and neurodegeneration, the temporal and spatial relationship between these biomarkers often deviates from the expected sequence [3, 4]. Recent evidence suggests that plasma phosphorylated tau 217 serves as a highly accurate proxy for brain pathology, but it may not fully account for the structural atrophy observed on neuroimaging in all patients [5, 6]. This discrepancy is frequently attributed to co-pathologies, such as limbic-predominant age-related TDP-43 encephalopathy, which can mimic or accelerate the Alzheimer's clinical syndrome [7]. Understanding these pathological mismatches is essential for transitioning from a uniform diagnostic model to a precision medicine approach in dementia care, allowing clinicians to better predict which patients will actually benefit from emerging therapies.